Journal: bioRxiv
Article Title: A combination TLR7/8 and RIG-I agonist adjuvant reverts asthmatic allergic sensitization and prevents aggravated influenza infection in OVA-sensitized mice
doi: 10.1101/2025.06.23.659362
Figure Lengend Snippet: A) Daily mice bodyweights measured from 0DPI to 5DPI. B) Lung viral titers expressed as plaque forming units per mL (PFU/mL) measured in lung homogenates at 5DPI. Limit of detection = 40 PFU/mL. C) Trivalent Influenza Vaccine (containing NC99 HA)-binding total IgG measured at 5DPI represented as Area under the curve (AUC) of the optical density at 450 nm (OD450) minus the background noise (OD650). Lung cell subpopulations at 5DPI are presented in panels D to H. D) Percentage of lung total T-cells (CD3+, gating: Live> CD45 + > CD3 + ). E) Percentage of T-cell subpopulations represented as the mean % of CD3% cells per group: CD4 + cells (Gating: Live> CD45 + > CD3 + >CD4 + CD8 - ), CD8 + cells (Gating: Live> CD45 + > CD3 + >CD4 - CD8 + ), T regs (Gating: Live> CD45 + > CD3 + >CD4 + CD8 - >FoxP3 + ). CD3 + cells not included in any of the three subpopulations are categorized as “unassigned”. Statistical analysis: for comparisons among groups at several time points: Two-way ANOVA with Tukey’s multiple comparisons test using the OVA-Alum (IP) group as control for multiple comparisons. Color of the significance markers indicates the comparison they represent; for comparisons among groups at a specific time point: Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparisons test using the OVA-Alum (IP) group as control for multiple comparisons. Significance is represented as:*p = 0.05 to 0.01, **p = 0.01 to 0.001, ***p = 0.001 to 0.0001, ***p < 0.0001.
Article Snippet: For the depletion of the different T-cell subpopulations, mice were injected intraperitoneally with either CD4 depleting antibody BioXCell #BP0003-1 (clone YTS 177) with a dosing of 500 μg in 100 μL PBS, CD8 depleting antibody BioXCell #BE0223 (clone 53-5.8) with a dosing 250 μg in 100μL PBS or a combination of both, 72 and 24 hr prior to the first OVA challenge.
Techniques: Binding Assay, Control, Comparison